Alpha¹ by KaimenConfidential

Kaimen Rigor review

A Multicomponent Intervention to Improve Maternal Infection Outcomes.

Lissauer D, Gadama L, Waitt C, Whyte S, Burnside G, Anilkumar A, Makuluni R, Okwaro P, Yang L, Waitt P, Musopole O, Bilesi R, Maseko B, Lwasa J, Mugahi R, Olaro C, Lamorde M, Makuta M, Kachiwaya C, Mkandawire T, Malunga A, Chitsulo N, Abitimo P, Ayabo T, Weeks A, Martin J, Hemming K, Gallos I, Monk EJM, Riches J, Chapuma C, Nanyondo S J, Lorencatto F, Monahan M, Allegranzi B, Dunlop C, Atkins L, Rosala-Hallas A, Roberts T, Gamble C, Malata A, Desmond N, Kommwa E, Merriel A, Parry-Smith W, Smith R, Ndumu I, Williams E, Faque B, Banda G, Nyondo-Mipando AL, Twimukye A, Chater T, Diplas A, Brizuela V, Souza JP, Rylance J, Cheshire J, Hawker L, Coomarasamy A, Bonet M

DOI: 10.1056/NEJMoa2512698
Record issued: 2026-08-15
Engine: 7.39.0
Exported: 2026-09-20

Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/a4a7423b-4feb-43c7-acc6-4e1cb91fc92c is authoritative.

Kaimen Rigor review

Kaimen Rigor reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 12 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Findings by category

101ArithmeticNumerical inconsistencies 102OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted cluster-randomized trial with rigorous design, clear ethical approvals, and appropriate statistical methods. The main weaknesses are the lack of a clear data availability statement and minor reporting gaps (statistical software, demographics, reporting guideline).

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence to reconcile. The statistics verification component checked only 2 tests (both consistent); the remaining statistics are unverified. The citation check found no retracted or non-existent references.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Agent-written checks— recomputed from reported CIs / ratios by code the agent wrote

CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Primary outcome risk ratio p-value
“risk ratio, 0.68; 95% CI, 0.55 to 0.83; P<0.001”
Find in source
Taken as given: The risk ratio is 0.68 with 95% CI 0.55 to 0.83.; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed p-value from the reported risk ratio and 95% CI using the pCI function for a ratio.
How we recomputed it: pCI(0.68, 0.55, 0.83, 1)
CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2
Severe infection-related morbidity risk ratio p-value
“risk ratio, 0.68; 95% CI, 0.55 to 0.84”
Find in source
Taken as given: The risk ratio is 0.68 with 95% CI 0.55 to 0.84.; The CI is two-sided at 95%.; The p-value is two-tailed.
Method: Recomputed p-value from the reported risk ratio and 95% CI using the pCI function for a ratio.
How we recomputed it: pCI(0.68, 0.55, 0.84, 1)

lowinternal contradiction
The number of live births in Table 1 (94,730 intervention, 95,770 control) sums to 190,500, which matches the baseline phase total. However, the intervention phase totals (124,298 and 116,596) sum to 240,894, which matches the stated total. This is consistent.
“There were a total of 431,394 women with live births during the study (190,500 in the baseline phase and 240,894 in the intervention phase, .)”
Table 1Find in source

Overstated conclusions

1 finding · worst low

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

partialReviewer 1
The intervention improved early detection of sepsis and use of the FAST-M bundle.
Some implementation outcomes improved (e.g., complete observations at admission), but the difference in antibiotics within 1 hour was not statistically significant (mean difference 8%, 95% CI -3% to 19%).
Evidence: Complete observations at admission: 48% vs 15%, mean difference 32% (95% CI 25-40%); antibiotics within 1 hour: 44% vs 38%, mean difference 8% (95% CI -3% to 19%).
“Several measures related to Goal 3 also supported primary outcomes findings; for example, complete observations at admission in 48% vs 15%, respectively (mean difference 32%; 95% CI 25% to 40%) and, among patients with suspected sepsis, antibiotics administered within 1 hour in 44% vs 38%, respectively (mean difference 8%; 95% CI -3% to 19%).”
ResultsFind in source
partialReviewer 2
The intervention is feasible beyond the trial setting.
The paper argues feasibility based on minimal additional resources, but this is an inference from the trial context and not directly tested.
Evidence: Discussion paragraph 3.
“The intervention involved the provision of relatively few additional resources beyond what was generally available within the hospital systems, suggesting feasibility beyond the trial setting.”
DiscussionFind in source
supportedReviewers 1, 2
The APT-Sepsis intervention reduced the composite of maternal infection-related mortality and severe morbidity compared to usual care.
The primary outcome analysis shows a statistically significant reduction with a risk ratio of 0.68 (95% CI 0.55-0.83, P<0.001), directly supporting the claim.
Evidence: Primary outcome result: 1752/124,298 (1.4%) vs 2208/116,596 (1.9%), RR 0.68 (0.55-0.83), P<0.001.
“The incidence of maternal infection–related mortality or severe morbidity was 1.4% in the intervention group and 1.9% in the usual care group (risk ratio, 0.68; 95% confidence interval, 0.55 to 0.83; P<0.001).”
AbstractFind in source
supportedReviewers 1, 2
The effect was consistent across countries and facility size.
The paper states the effect was generally consistent across subgroups, and forest plots are referenced, though not all subgroup results are shown in the text.
Evidence: Subgroup analyses by country and facility size are mentioned, with forest plots in Figure 3.
“This effect appeared generally consistent between countries ( and ) and across small, medium and large facilities.”
ResultsFind in source
supportedReviewers 1, 2
The effect was sustained over time.
The paper shows a progressive decrease in incidence and increasing effect size over the intervention period, supporting the claim of sustainability.
Evidence: Incidence decreased from 2.4% at baseline to 0.9% in the final month; risk ratio improved from 0.92 to 0.53.
“The incidence of the primary outcome in the intervention group progressively decreased following randomization, with a mean rate of 2.4% at baseline, 2% in the first month following implementation and completion of the transition phase, and 0.9% in the final month of the study.”
ResultsFind in source
supportedReviewer 1
The intervention improved hand hygiene compliance.
Implementation outcome shows a significant improvement in hand hygiene compliance (mean difference 14%, 95% CI 10-19%).
Evidence: Hand hygiene compliance: 33% vs 15%, mean difference 14% (95% CI 10-19%).
“Mean hand hygiene compliance (Goal 1) was 33% in the intervention sites compared to 15% in the usual care sites (mean difference 14%; 95% CI 10% to 19%).”
ResultsFind in source
supportedReviewer 1
The intervention improved appropriate antibiotic prophylaxis at cesarean section.
Implementation outcome shows a significant improvement in correct antibiotic prophylaxis (mean difference 15%, 95% CI 4-26%).
Evidence: Correct cesarean section antibiotic prophylaxis: 74% vs 58%, mean difference 15% (95% CI 4-26%).
“Appropriate antibiotic prophylaxis was appropriately administered prior to cesarean section (Goal 2) in 74% and 58% of patients, respectively (mean difference 15%; 95% CI 4% to 26%).”
ResultsFind in source
supportedReviewer 2
The intervention improved hand hygiene compliance, antibiotic prophylaxis, and sepsis management.
Implementation outcomes show significant improvements in hand hygiene, antibiotic prophylaxis, and vital sign recording, though some measures like antibiotics within 1 hour did not reach statistical significance.
Evidence: Table 2 implementation outcomes.
“Mean hand hygiene compliance (Goal 1) was 33% in the intervention sites compared to 15% in the usual care sites (mean difference 14%; 95% CI 10% to 19%).”
ResultsFind in source

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

ADEQUATESurrogate endpoint
The primary outcome is a composite of hard clinical outcomes: infection-related maternal mortality, infection-related maternal near-miss, and severe infection (deep surgical/perineal site or body-cavity infection). These are clinical events, not surrogate biomarkers. The intervention also shows target engagement through implementation outcomes (e.g., hand hygiene compliance, antibiotic prophylaxis, vital sign recording) that are directly linked to the intervention's mechanisms.
“The primary outcome was infection-related maternal death or severe morbidity. This was defined as a composite of infection-related maternal mortality, infection-related maternal “near-miss” events, and severe infection (deep surgical-site, deep perineal or body-cavity infection) during pregnancy, childbirth or within 42 days of pregnancy ending, at any time up to 28 days of discharge (whichever occurred first).”
Find in source
ADEQUATEEffect size
The primary outcome showed a risk ratio of 0.68 (95% CI 0.55-0.83) with absolute rates of 1.4% vs 1.9%, representing a 32% relative reduction. This is statistically significant and clinically meaningful, as it reflects a reduction in serious maternal morbidity and mortality. The effect was consistent across subgroups and increased over time.
“The incidence of maternal infection–related mortality or severe morbidity was 1.4% in the intervention group and 1.9% in the usual care group (risk ratio, 0.68; 95% confidence interval, 0.55 to 0.83; P<0.001).”
Find in source

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The introduction cites multiple studies and WHO recommendations on maternal infection and sepsis, highlighting the burden and gaps in care. It logically links these to the need for a multicomponent intervention and states the study objective. Limitations of prior work (e.g., lack of established effect of maternal sepsis bundles) are acknowledged.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the intervention.

Evidence

“The World Health Organization (WHO) has issued recommendations on adherence to hand-hygiene standards and evidence-based practices to prevent and treat maternal infections.”

Introduction ¶1Find in source

“A maternal sepsis bundle has been developed specifically for low resource settings, but its effect on maternal outcomes has not been established.”

Introduction ¶4Find in source

“We conducted a large cluster-randomized trial in Malawi and Uganda to evaluate whether implementation of the APT-Sepsis program in health facilities would reduce infection-related maternal mortality and severe morbidity.”

Introduction ¶4Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise with extensive prior work cited and a logical rationale linking the intervention to the study objectives.

Evidence

“The World Health Organization (WHO) has issued recommendations on adherence to hand-hygiene standards and evidence-based practices to prevent and treat maternal infections.”

Introduction ¶1Find in source

paraphrase[Introduction, paragraph 4]

“The APT-Sepsis program was designed to address these deficiencies through an integrated, facility-level multicomponent intervention.”

“A maternal sepsis bundle has been developed specifically for low resource settings, but its effect on maternal outcomes has not been established.”

Introduction ¶3Find in source

Randomization used a minimization algorithm with a random element, and the unit of randomization (facility) is stated. Blinding is described for outcome adjudication, though outcome assessors were not blinded. A detailed power analysis is provided, including a pre-specified re-estimation. Inclusion/exclusion criteria for hospitals are specified. The analysis population (ITT) and handling of missing data (none reported) are adequate.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, blinding of outcome adjudication, and a pre-specified sample size calculation.

Evidence

“A minimization algorithm generated by an independent statistician was used to ensure balance between facilities allocated to the intervention and control groups within each country.”

MethodsFind in source

“If there was discordance in assessments, or if uncertainty in the causation was recorded by either group, the case was adjudicated by a separate case classification committee blinded to site allocation.”

MethodsFind in source

“We calculated that at least 60 clusters (a minimum of 30 in Malawi and 30 in Uganda) would be required for the trial to have 95% power, with 2 sided p < 0.05, to detect a 25% relative reduction in the composite primary outcome from 3% to 2.25%.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, blinding of outcome adjudication, pre-specified sample size, and appropriate analysis methods.

Evidence

“A minimization algorithm generated by an independent statistician was used to ensure balance between facilities allocated to the intervention and control groups within each country.”

MethodsFind in source

Statistical analysisFind in source

Sex is inherently female (pregnant women), and demographics such as age are not explicitly reported but the population is defined. Health status is captured through obstetric outcomes. Species/strain and housing are not applicable. Demographics are partially reported via facility characteristics and outcomes.

Sub-criteria

demographicsINADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthINADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The study reports relevant demographic and clinical characteristics of the participating women, though some details are limited.

Evidence

paraphrase[Abstract, Methods]

“The primary outcome was a composite of maternal infection-related mortality or severe morbidity ... among pregnant or recently pregnant women.”

“Postpartum hemorrhage (>1 liter) – no. (%) | 1,680 (1.8) | 1,355 (1.4)”

Table 1Find in source

absence[Table 1]

Age is not explicitly reported.

PASSReviewer 2· 85% conf

The study reports relevant demographic and clinical characteristics of the participating women, including age and obstetric history, though some details are limited.

Evidence

“Live births – no. | 94,730 | 95,770”

Table 1Find in source

absence[Results, Hospital and participant characteristics]

Maternal age and other demographics are not explicitly reported in the main text.

The paper lists specific ethics committees that approved the trial, including the University of Liverpool, WHO Ethics Review Committee, and national committees in Malawi and Uganda. It explains that individual patient consent was not obtained because the intervention targeted healthcare providers and components were considered best practice, with agreement obtained at national and facility levels. This is adequate for a cluster trial of a provider-level intervention.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approvals from multiple named committees are reported, and consent procedures are described.

Evidence

“The trial was approved by the University of Liverpool, the WHO Ethics Review Committee, the College of Medicine Research Ethics Committee in Malawi, the Infectious Diseases Institute Research Ethics Committee and Uganda National Council for Science and Technology in Uganda.”

MethodsFind in source

“Patients were not individually consented as the intervention was delivered to healthcare providers, and the components were considered best practice.”

MethodsFind in source

PASSReviewer 2· 95% conf

The trial received approval from multiple named ethics committees, and consent was appropriately waived with justification.

Evidence

MethodsFind in source

“Patients were not individually consented as the intervention was delivered to healthcare providers, and the components were considered best practice.”

MethodsFind in source

The paper describes the intervention components, including the FAST-M bundle with specific antibiotic regimens, and mentions that key resources such as antibiotics were obtained through usual procurement. It also describes the provision of soap, alcohol hand rub, thermometers, and blood pressure machines. However, specific product identifiers (e.g., manufacturer, catalog numbers) are not provided, which is typical for a health systems intervention.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 80% conf

The intervention components and key resources are described, though some details like specific product lots are not provided.

Evidence

“Antibiotics - According to source or if unknown ceftriaxone 2g IV OD and metronidazole 500mg IV TDS (or 400mg PO TDS) with additional singe dose gentamicin 5mg/kg IV if haemodynamically unstable.”

Figure 1Find in source

“Implementation strategies were developed from a behavior change perspective and include the following key components: hospital leadership engagement; program champions selected from existing facility staff; multi-disciplinary training with comprehensive training materials; implementation tools (eg FAST-M checklist); and performance feedback with dashboards and quarterly visits”

MethodsFind in source

PASSReviewer 2· 90% conf

The intervention components and key resources are described in sufficient detail, including the FAST-M bundle and training materials.

Evidence

“FAST-M bundle: To be completed within 1 hour. Fluids - 500ml crystalloid bolus, repeated if hypotension persists. Antibiotics - According to source or if unknown ceftriaxone 2g IV OD and metronidazole 500mg IV TDS (or 400mg PO TDS) with additional singe dose gentamicin 5mg/kg IV if haemodynamically unstable.”

Figure 1Find in source

absence[Methods, Statistical analysis]

Statistical software is not explicitly identified.

The primary analysis uses generalized linear mixed effects models with robust standard errors and marginal standardization. Effect sizes are reported as risk ratios with 95% CIs. Exact p-values are reported for the primary outcome. Software is not explicitly identified, but the methods are standard. Data presentation includes per-group Ns and CIs.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedNOT REPORTED

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported.

Evidence

“In the primary analysis, we used generalized linear mixed effects models incorporating a constrained baseline approach.”

Statistical analysisFind in source

“The primary outcome occurred in 1752 of 124,298 women (1.4%) in the intervention group and in 2208 of 116,596 (1.9%) in the usual care group (risk ratio, 0.68; 95% CI, 0.55 to 0.83; P<0.001)”

ResultsFind in source

absence[Methods, Statistical analysis]

Statistical software is not identified.

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values for the primary outcome and effect sizes with confidence intervals.

Evidence

“The primary outcome occurred in 1752 of 124,298 women (1.4%) in the intervention group and in 2208 of 116,596 (1.9%) in the usual care group (risk ratio, 0.68; 95% CI, 0.55 to 0.83; P<0.001)”

ResultsFind in source

“In the primary analysis, we used generalized linear mixed effects models incorporating a constrained baseline approach.”

Statistical analysisFind in source

absence[Methods, Statistical analysis]

Statistical software is not mentioned.

The paper states that the protocol is available with the full text, but does not provide a clear data availability statement. No repository deposits or accession numbers are mentioned. Code sharing is not applicable as no custom code is described.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementINADEQUATE

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, and no data or code repositories are mentioned.

Evidence

“The first and last author, and the trial statisticians from the Liverpool Clinical Trials Centre vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol, available with the full text of this article at NEJM.org.”

MethodsFind in source

absence[Entire paper]

No data repository is mentioned.

WARNReviewer 2· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned.

Evidence

absence[Entire paper]

No data availability statement is present.

The trial is registered (ISRCTN42347014). Methods are comprehensive. Limitations are explicitly discussed, including lack of blinding and potential underreporting. Conclusions are proportional to the evidence. Funding and COI are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional.

Evidence

“APT-Sepsis ISRCTN number, ISRCTN42347014.”

ConclusionFind in source

“The trial has several limitations. The multicomponent nature of the intervention precludes attribution of the effect to individual elements.”

Discussion ¶4Find in source

“This project is supported by the Joint Global Health Scheme with funding from the UK Foreign, Commonwealth and Development Office, the UK Medical Research Council (MRC), The UK Department of Health and Social Care through the National Institute of Health Research (NIHR) and Wellcome (Grant ref: MRV005782/1)”

Supplementary materialFind in source

PASSReviewer 2· 90% conf

The paper is transparent about methods, limitations, and funding, and reports all pre-specified outcomes.

Evidence

“APT-Sepsis ISRCTN number, ISRCTN42347014.”

AbstractFind in source

“The trial has several limitations. The multicomponent nature of the intervention precludes attribution of the effect to individual elements.”

Discussion ¶4Find in source

Supplementary materialFind in source

Registered (1 ID: ISRCTN). No reporting guideline cited.

ISRCTN

ISRCTN42347014

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 30 references by DOI: 21 verified — 9 no DOI (shown, not verified).

NO DOI
Statement on maternal sepsis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
2030 global agenda for sepsis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Improving the prevention, diagnosis, and clinical management of sepsis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Accelerate progress towards reducing maternal, newborn, and child mortality in order to achieve Sustainable Development Goal targets 3.1 and 3.2
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Too little, too late: the recurrent theme in maternal deaths due to sepsis
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
WHO guidelines on hand hygiene in health care
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
WHO recommendations for the prevention and treatment of maternal peripartum infections
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
Abortion care guideline
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
NO DOI
WHO recommendation on antibiotic prophylaxis during labour for vaginal birth
No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly typo, clarity, consistency.

MINORtypoFigure 1 (in paper text)
“singe dose gentamicin”
→ single dose gentamicin
Typographical error.
MINORconsistencyTable 2
“116596”
→ 116,596
Missing comma for consistency with other numbers.
MINORclarityMethods, Statistical analysis
“The second minimization factor (proportion of births with the composite primary outcome) was not included as it was already in the model as the outcome variable.”
→ Clarify that the outcome variable is the composite primary outcome, not the proportion.
Potential ambiguity.
MINORtypoFigure 1 legend
“singe dose gentamicin”
→ single dose gentamicin
Typographical error in the FAST-M bundle description.
MINORclarityMethods, Statistical analysis
“The second minimization factor (proportion of births with the composite primary outcome) was not included as it was already in the model as the outcome variable.”
→ The second minimization factor (proportion of births with the composite primary outcome) was not included as a covariate because it was already the outcome variable in the model.
Clarify the wording to avoid ambiguity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (data availability, software identification, demographics) as transparency issues, not validity threats. No erratum is warranted for the statistical results, but a data availability statement would improve reproducibility.

1.
HIGHdata code
Add a clear data availability statement in the Methods or a dedicated section, specifying that de-identified individual participant data may be available upon reasonable request to the trial steering committee, with conditions and timeframe.
The current statement only mentions protocol availability, not data access, which is a transparency gap for a data-driven trial.
2.
HIGHstatistics
Mention the statistical software (e.g., Stata, R) and version used for analyses in the Statistical analysis section.
Identifying the software is standard for reproducibility and was flagged by both reviewers.
3.
MEDIUMreporting
Explicitly state adherence to CONSORT guidelines for cluster-randomized trials, and include the CONSORT checklist as supplementary material.
Reporting guidelines improve transparency and are expected for RCTs; currently not mentioned.
4.
MEDIUMreporting
Provide more detailed demographic characteristics of the study population (e.g., maternal age, parity, comorbidities) in Table 1 or supplementary tables.
Demographics are only partially reported; age and other key variables are missing from the main text.
5.
MEDIUMstatistics
Report exact p-values for secondary outcomes or clearly state that they are not adjusted for multiplicity and should be interpreted with caution.
Some secondary outcomes lack exact p-values, which limits interpretability.
6.
MEDIUMreporting
Include a statement about the availability of the trial protocol and statistical analysis plan, possibly with a link or DOI.
The protocol is mentioned but not linked; a DOI would improve accessibility.
7.
LOWcopyedit
Fix the typo 'singe dose' to 'single dose' in Figure 1 and its legend.
Typographical error in the FAST-M bundle description.
8.
LOWcopyedit
Add a comma to '116596' in Table 2 for consistency with other numbers (e.g., '116,596').
Inconsistent formatting in the table.
9.
LOWcopyedit
Clarify the sentence in Methods, Statistical analysis about the second minimization factor to avoid ambiguity.
The current wording could be misread; suggest rephrasing to 'was not included as a covariate because it was already the outcome variable in the model.'

Full text (40,744 chars)Analyzed: Aug 15, 2026

RigorReviewer 1

RigorReviewer 2

RigorPre-Submission Reviewer

CopyeditAgent Scribe

CitationsCitation Integrity

StatisticsStatistics Consistency

PreregistrationDeterministic check· no model (rule-based)

The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”

How stars are deducted

Reporting — 8 dimensionseach dimension that fully fails−½★
each dimension partially met−¼★
Statistics · Integrity · Claimseach serious problem−1★
each medium problem−½★
Citationseach retracted or unverifiable reference−¼★
Copyeditonly when the manuscript needs a full edit−½★

The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.

The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.

The eight reporting dimensions

Scientific PremisePrior work, rationale, and how it addresses gaps.

Study Design & RigorRandomization, blinding, power, controls, replication.

Biological VariablesSex, age, species/strain, housing, demographics.

Ethical ApprovalsIRB/IACUC approval, informed consent, regulatory compliance.

Key ResourcesAntibodies, cell lines, organisms, software — identified with persistent IDs.

Statistical ReportingNamed tests, exact p-values, effect sizes, plausible summary stats.

Data & Code AvailabilityAvailability statements, repositories, accession numbers, shared code.

Reporting TransparencyMethods, registration, guidelines, outcomes, limitations, funding/COI.

Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.

This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.

A Multicomponent Intervention to Improve Maternal Infection Outcomes.

DOI

10.1056/NEJMoa2512698

Record issued

2026-08-15

Engine

7.39.0

Exported

2026-09-20